Affinage

CD300A

CMRF35-like molecule 8 · UniProt Q9UGN4

Length
299 aa
Mass
33.2 kDa
Annotated
2026-06-09
71 papers in source corpus 27 papers cited in narrative 28 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CD300a (originally IRp60) is a type I transmembrane ITIM-bearing inhibitory immunoreceptor that restrains activation across a broad range of immune cells by sensing aminophospholipids displayed on apoptotic, activated, and infected cells (PMID:10540326, PMID:22302738). Its extracellular IgV domain directly binds phosphatidylserine (PS) and phosphatidylethanolamine (PE) exposed on dead cells, with mutagenesis defining a ligand cavity that accommodates the hydrophilic phospholipid headgroups (PMID:22302738); the same residues underlie a graded affinity hierarchy that distinguishes CD300a from its activating paralog CD300C (PMID:23372157). Ligand engagement drives Lck-dependent tyrosine phosphorylation of the cytoplasmic ITIMs, which dock SHP-1 as the critical effector phosphatase (SHP-2 and SHIP-1 contribute in specific contexts), thereby terminating calcium influx and downstream signaling (PMID:22537350, PMID:10540326). Through this circuit CD300a inhibits an array of activating pathways, including FcεRI- and Kit-driven mast cell responses, eosinophil cytokine signaling, BCR-mediated B cell proliferation, FcγRIIa signaling, and MyD88-dependent TLR4/TLR9 inflammation (PMID:16339535, PMID:18424727, PMID:16254138, PMID:21482706, PMID:17588661, PMID:22043923). In myeloid cells CD300a additionally restrains efferocytosis by antagonizing the activating CD300b-DAP12 pathway, and its expression is directly controlled at the transcriptional level by PPARβ/δ (PMID:34652960, PMID:24958459). Pathogens exploit this inhibition: enveloped viruses such as dengue use CD300a-phospholipid binding to enhance clathrin-mediated entry, and viral kinases increase CD300a ligand display to shield infected cells from NK lysis (PMID:26468529, PMID:26581992). The receptor thereby functions as a central rheostat dampening allergic, antitumor, antibacterial, and ischemic inflammatory responses (PMID:25911756, PMID:23640773, PMID:22826299).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 1999 High

    Established CD300a as a bona fide inhibitory NK receptor by linking its phosphorylation to recruitment of SH2-domain phosphatases and functional suppression of cytotoxicity.

    Evidence mAb cross-linking, co-IP of SHP-1/SHP-2 after pervanadate, and cytotoxicity assays in human NK cells

    PMID:10540326

    Open questions at the time
    • Ligand for the receptor was unknown
    • Relative importance of SHP-1 vs SHP-2 not resolved
  2. 2005 High

    Extended the inhibitory role beyond NK cells, showing CD300a engagement suppresses FcεRI-driven degranulation, SCF survival signaling, and eosinophil activation, with cell-type-specific phosphatase usage.

    Evidence Antibody cross-linking with calcium, degranulation, transmigration and JAK2/ERK/p38 readouts plus co-IP in mast cells and eosinophils; murine allergic peritonitis model

    PMID:16254138 PMID:16339535

    Open questions at the time
    • Physiological ligand still undefined
    • Mechanism of selective SHP-1 vs SHP-2 recruitment unclear
  3. 2006 Medium

    Provided the first structural description of the extracellular domain, confirming an immunoglobulin-like fold and monomeric solution behavior.

    Evidence SAXS and homology modeling of recombinant refolded ectodomain

    PMID:16949664

    Open questions at the time
    • No high-resolution crystal structure
    • No ligand-bound structure or mutagenesis validation
  4. 2008 High

    Demonstrated context-dependent signaling outputs, including SHIP-1 (not SHP-1) recruitment upon Kit co-aggregation and cytokine modulation in plasmacytoid DCs.

    Evidence Bispecific Kit×CD300a antibodies with co-IP and mast cell assays; cross-linking with cytokine ELISA in pDCs

    PMID:18424727 PMID:18535206

    Open questions at the time
    • Determinants of SHIP-1 vs SHP-1 selection unresolved
    • Endogenous ligand triggering these responses unknown
  5. 2011 High

    Identified phosphatidylserine on apoptotic cells as a direct ligand and confirmed inhibitory function in B cells, resolving the long-standing ligand question.

    Evidence CD300a-Fc binding assay with PS-dependent SHP-1 co-IP; BCR co-ligation with calcium/NFAT reporters and siRNA knockdown in primary B cells

    PMID:21482706 PMID:22185693

    Open questions at the time
    • Whether other phospholipids are recognized not yet tested
    • Structural basis of PS recognition undefined
  6. 2012 High

    Defined the molecular ligand-recognition mechanism and the core inhibitory signaling module, establishing PS/PE binding via a headgroup cavity, Lck-dependent ITIM phosphorylation, and SHP-1 as the dominant effector.

    Evidence SPR, ELISA, ultracentrifugation, site-directed mutagenesis and structural modeling; chimeric KIR-CD300a/ITIM-mutant and phosphatase-deficient cell systems; TLR reporter assays in monocytic lines; CD300a-KO mast cell sepsis model

    PMID:22043923 PMID:22302738 PMID:22537350 PMID:22826299

    Open questions at the time
    • No co-crystal structure of ligand engagement
    • Quantitative phospholipid selectivity in membranes not fully defined
  7. 2013 Medium

    Linked the PS-CD300a axis to antitumor immunity and uncovered an actin-cytoskeleton-associated role in monocyte migration.

    Evidence Anti-CD300a/PS blocking antibodies in NK tumor-killing assays; confocal colocalization, cosedimentation and transendothelial migration assays with siRNA in monocytes

    PMID:23640773 PMID:24058511

    Open questions at the time
    • Mechanism connecting CD300a to F-actin remodeling not defined
    • In vivo relevance of tumor PS-CD300a blockade not tested here
  8. 2014 High

    Identified PPARβ/δ as a direct transcriptional regulator of CD300a and tied receptor deficiency to TLR4-MyD88-driven chronic intestinal inflammation.

    Evidence CD300a-KO mice on high-fat diet, bone marrow transplantation, LPS stimulation and PPARβ/δ regulation assays

    PMID:24958459

    Open questions at the time
    • Direct PPARβ/δ binding elements not mapped
    • Generalizability of transcriptional control to other cell types unknown
  9. 2015 High

    Showed CD300a binds enveloped virus particles and that viruses exploit ligand display, while also defining its role in allergic airway inflammation through dendritic cells.

    Evidence DENV/WNV/CHIKV binding, clathrin inhibition and phospholipid-binding mutagenesis; US3 kinase/PAK NK protection assays; CD300a-KO alum+OVA airway model with iDC-T cell co-culture

    PMID:25911756 PMID:26468529 PMID:26581992

    Open questions at the time
    • Whether CD300a signals during viral entry or acts only as attachment factor unclear
    • Host counter-regulation of viral ligand induction unexplored
  10. 2021 High

    Expanded the efferocytosis-restraining function across disease models and defined intracellular and cross-receptor mechanisms (CD300b-DAP12 antagonism, endosomal TLR3-TRIF suppression).

    Evidence CD300a-KO MCAO, UPEC, MSU-gout, and B16 melanoma models with efferocytosis, phagocytosis, caspase-8, IFN-β/Treg and DAMP readouts; antibody blockade phenocopies

    PMID:34002852 PMID:34268737 PMID:34652960 PMID:34751648

    Open questions at the time
    • How CD300a is internalized and routed to endosomes mechanistically undefined
    • Balance between inhibitory and pro-apoptotic functions across tissues unclear
  11. 2023 Medium

    Positioned CD300a within a PPARβ/δ→CD300a→SHP1/Syk signaling axis controlling mast cell degranulation in vivo.

    Evidence PPARβ/δ agonist GW0742 with PPARβ/δ and CD300a siRNA epistasis and SHP1/Syk phosphorylation in a germinal matrix hemorrhage rat model

    PMID:37995951

    Open questions at the time
    • Direct biochemical link between CD300a and Syk dephosphorylation not shown
    • Single-model pharmacological epistasis
  12. 2025 Medium

    Revealed cooperativity with the paralog CD300lf and a broader lipid ligand repertoire (ceramide) in setting the threshold for mast cell activation.

    Evidence Imaging and flow analyses of single and double CD300a/CD300lf KO BMMCs with PS/ceramide colocalization and a passive systemic anaphylaxis model

    PMID:40073110

    Open questions at the time
    • Molecular basis of CD300a/CD300lf cooperation undefined
    • Whether ceramide is a direct CD300a ligand not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • The structural basis of phospholipid headgroup discrimination, the rules governing context-specific phosphatase selection (SHP-1 vs SHP-2 vs SHIP-1), and the trafficking machinery routing CD300a to endosomes remain unresolved.
  • No ligand-bound atomic structure
  • Predictive model for effector phosphatase choice lacking
  • Internalization/sorting mechanism uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008289 lipid binding 4 GO:0098772 molecular function regulator activity 4 GO:0060089 molecular transducer activity 3 GO:0001618 virus receptor activity 1
Localization
GO:0005886 plasma membrane 3 GO:0005768 endosome 1 GO:0005856 cytoskeleton 1
Pathway
R-HSA-168256 Immune System 5 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 2 R-HSA-5357801 Programmed Cell Death 1
Partners
CD300BCD300LFFCGRIIAKITLCKSHIP-1SHP-1SHP-2

Evidence

Reading pass · 28 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 IRp60 (CD300a) is an inhibitory receptor on human NK cells that, upon sodium pervanadate treatment, becomes tyrosine phosphorylated and associates with the SH2-containing phosphatases SHP-1 and SHP-2, thereby inhibiting NK cell cytotoxicity. Monoclonal antibody generation, cross-linking experiments, co-immunoprecipitation of SHP-1/SHP-2 after pervanadate treatment, cytotoxicity assays European journal of immunology High 10540326
2005 IRp60 (CD300a) cross-linking on human mast cells inhibits IgE-induced degranulation and SCF-mediated survival via tyrosine phosphorylation, phosphatase (SHP-1/SHP-2) recruitment, and termination of cellular calcium influx. Cross-linking with anti-IRp60 antibodies, flow cytometry for phosphorylation and calcium influx, degranulation assays (tryptase and IL-4 release), murine allergic peritonitis model with LMIR1 neutralization Journal of immunology (Baltimore, Md. : 1950) High 16339535
2005 IRp60 (CD300a) cross-linking on human eosinophils inhibits eotaxin-dependent transmigration, blocks anti-apoptotic cytokine effects, inhibits IL-5-mediated JAK2 phosphorylation, and inhibits ERK1/2 and p38 phosphorylation; CD300a underwent tyrosine phosphorylation and recruited SHP-1 but not SHP-2 on eosinophils. Cross-linking with anti-IRp60 mAbs, transmigration assays, apoptosis assays, cytokine release assays, Western blotting for JAK2/ERK1/2/p38 phosphorylation, co-immunoprecipitation for SHP-1/SHP-2 Blood High 16254138
2006 Solution structure of the IRp60 (CD300a) extracellular immunoglobulin-like domain was determined by small-angle X-ray scattering (SAXS); the protein is monomeric in solution with a molecular shape characteristic of immunoglobulin-like structures. Recombinant protein expression in E. coli, refolding, small-angle X-ray scattering (SAXS), homology modeling validated against SAXS data International journal of biological macromolecules Medium 16949664
2007 CD300a expression on human neutrophils is rapidly increased by LPS and GM-CSF stimulation through translocation of an intracellular pool to the cell surface, and co-ligation of CD300a with FcγRIIa (CD32a) inhibits FcγRIIa-mediated signaling but does not inhibit TLR4-mediated ROS production. Flow cytometry, HL-60 differentiation model, co-ligation experiments, ROS production assays Molecular immunology Medium 17588661
2008 CD300a/c cross-linking on plasmacytoid dendritic cells reduces TNF-α and increases IFN-α secretion following TLR7/TLR9 stimulation; IFN-α itself down-regulates CD300a/c expression, establishing a feedback loop. Flow cytometry for surface expression, cross-linking with anti-CD300a/c antibodies, cytokine ELISA, neutralizing antibody experiments Blood Medium 18535206
2008 CD300a co-aggregation with Kit via a bispecific antibody results in Kit-mediated tyrosine phosphorylation of CD300a and recruitment of SHIP-1 (but not SHP-1), inhibiting SCF-induced mast cell differentiation, survival, and activation, and suppressing constitutive Kit signaling in HMC-1 leukemic cells. Bispecific antibody fragments (Kit×CD300a), Western blotting for phosphorylation, co-immunoprecipitation for SHIP-1/SHP-1, mast cell differentiation/survival/activation assays, murine cutaneous anaphylaxis model Journal of immunology (Baltimore, Md. : 1950) High 18424727
2011 CD300a extracellular domain (as a CD300a-Fc chimeric fusion protein) specifically binds phosphatidylserine (PS) exposed on apoptotic cells, and PS binding induces SHP-1 recruitment by CD300a in mast cells in response to LPS. CD300a-Fc fusion protein binding assay, co-immunoprecipitation for SHP-1 after PS stimulation Biochemical and biophysical research communications Medium 22185693
2011 Co-ligation of BCR and CD300a on B cells inhibits Ca2+ mobilization and NFAT transcriptional activity; siRNA-mediated knockdown of CD300a in primary B cells resulted in increased BCR-mediated proliferation, confirming CD300a's inhibitory role in B cell signaling. Co-ligation with anti-CD300a and anti-BCR antibodies, calcium flux measurements, NFAT reporter assays, siRNA knockdown, proliferation assays Blood High 21482706
2012 CD300a binds phosphatidylethanolamine (PE) and phosphatidylserine (PS) exposed on dead cells, as identified by surface plasmon resonance, ultracentrifugation, ELISA, and reporter cell assays; mutational analysis identified residues forming a cavity where the hydrophilic heads of PE and PS penetrate; CD300a down-regulates macrophage phagocytosis of apoptotic cells. Surface plasmon resonance, ultracentrifugation, ELISA, reporter cell assays, site-directed mutagenesis, structural modeling, phagocytosis assays with CD300a-Ig fusion protein Blood High 22302738
2012 CD300a on mast cells acts as a non-phagocytic PS receptor; PS-CD300a interaction delivers an inhibitory signal suppressing LPS-induced inflammatory cytokine and chemokine production in mast cells; in a cecal ligation and puncture model, CD300a-deficient peritoneal mast cells produced more chemoattractant and recruited more neutrophils, improving bacterial clearance and survival. CD300a-deficient mice, cecal ligation and puncture model, cytokine/chemokine measurements, neutrophil recruitment assays, antibody blockade of CD300a-PS interactions The Journal of experimental medicine High 22826299
2012 CD300a mediates inhibitory signaling through ITIMs that require Lck-mediated tyrosine phosphorylation to create docking sites for SHP-1 and SHP-2; SHP-1, but not SHP-2 or SHIP, is the critical phosphatase for CD300a's inhibitory activity in T and B cells. Chimeric KIR-CD300a receptor in Jurkat T cells, ITIM mutagenesis, siRNA knockdown of SHP-1/SHP-2, DT40 phosphatase-deficient cell lines, superantigen-stimulated TCR signaling assays BMC immunology High 22537350
2012 CD300a selectively blocks TLR4-mediated and TLR9-mediated (MyD88-dependent) but not TLR3-mediated (TRIF-dependent) pro-inflammatory signaling in monocytic cell lines, acting primarily through SHP-1; ITIM peptides from CD300a mimicked this selective inhibition. TLR stimulation of THP-1 and U937 cells, NF-κB luciferase reporter assays, MyD88/TRIF overexpression, synthetic ITIM peptides, signaling inhibitors, Western blotting Immunology High 22043923
2013 PS expressed on tumor cells interacts with CD300a on NK cells to inhibit NK cell-mediated tumor killing; blocking the PS-CD300a interaction increased NK cell killing of tumor cells. Generation of specific anti-CD300a mAbs, NK cell clone characterization, binding assays with tumor cells, NK cytotoxicity assays with PS/CD300a blocking antibodies European journal of immunology Medium 23640773
2013 CD300a colocalized and cosedimented with actin filaments in human monocytes; CD300a activation by antibody caused F-actin cytoskeleton alterations and reduced monocyte transendothelial migration; siRNA-mediated downregulation of CD300a increased the rate of migration. siRNA knockdown, antibody-mediated receptor engagement, confocal colocalization, cosedimentation assays, transendothelial migration assays PloS one Medium 24058511
2013 CD300C delivers a FcRγ-dependent activating signal in mast cells and monocytes; PE and apoptotic cells are ligands for both CD300A and CD300C, but CD300A binds PE more strongly than CD300C; differential recognition depends on residues CD300A(F56-L57) vs CD300C(L63-R64); co-expression of full-length CD300A dampens CD300C-PE-mediated signaling. Antibody generation with epitope mapping, chimeric reporter cell lines expressing CD300A or CD300C extracellular domains with CD3ζ, GFP reporter assays, phospholipid binding assays, cytokine production assays, site-specific amino acid analysis The Journal of biological chemistry High 23372157
2014 PPARβ/δ directly regulates CD300a transcription in macrophages; CD300a-deficient mice on high-fat diet develop chronic intestinal inflammation with prolonged IL-6 secretion from macrophages in response to LPS/TLR4-MyD88 signaling; bone marrow transplantation confirmed the phenotype originates from CD300a deficiency in leukocytes. CD300a-deficient mice, high-fat diet model, bone marrow transplantation, LPS stimulation assays, cytokine measurements, PPARβ/δ direct regulation assay Scientific reports High 24958459
2015 CD300a directly binds dengue virus (DENV) particles via recognition of PE (primarily) and PS on viral envelopes, enhances DENV internalization through clathrin-mediated endocytosis, and facilitates infection of all four DENV serotypes as well as West Nile virus and Chikungunya virus; mutation of IgV domain residues critical for phospholipid binding abrogated CD300a-mediated enhancement of infection. CD300a overexpression in cell lines, direct binding assays with DENV particles, clathrin inhibition, site-directed mutagenesis of phospholipid-binding residues, anti-CD300a antibody inhibition of primary macrophage infection Journal of virology High 26468529
2015 US3 protein kinase of pseudorabies virus triggers increased binding of inhibitory NK receptor CD300a to the surface of infected cells via aminophospholipid ligands and group I p21-activated kinases (PAKs), providing protection of infected cells against NK cell-mediated lysis. US3 kinase expression in infected cells, CD300a binding assays, NK cytotoxicity assays, PAK inhibitor experiments, aminophospholipid competition assays Journal of virology Medium 26581992
2015 CD300a expressed on inflammatory dendritic cells (iDCs) binds PS on apoptotic cells induced by alum adjuvant in the peritoneal cavity; CD300a-deficient mice showed significantly decreased eosinophil infiltration, serum IgE, and airway hyperreactivity after alum+OVA immunization; iDCs from CD300a-deficient mice induced less IL-4 from naive CD4+ T cells; antibody blockade of CD300a-PS interactions inhibited allergic airway inflammation. CD300a-deficient mice, allergic airway inflammation model, flow cytometry, OT-II T cell co-culture, anti-CD300a neutralizing antibody blockade Journal of immunology (Baltimore, Md. : 1950) High 25911756
2021 CD300a on brain myeloid cells inhibits signaling through the CD300b-DAP12 pathway to prevent efferocytosis of apoptotic cells; CD300a deficiency enhanced efferocytosis by infiltrating myeloid cells within 1 hour after MCAO, reduced DAMP release, and ameliorated neurological deficit; anti-CD300a neutralizing antibody recapitulated these benefits. CD300a-deficient mice, middle cerebral artery occlusion (MCAO) model, efferocytosis assays, DAMP measurements, CD300b-DAP12 signaling pathway analysis, anti-CD300a neutralizing antibody treatment Science immunology High 34652960
2021 CD300a on dendritic cells inhibits tumor-derived extracellular vesicle (TEV)-mediated TLR3-TRIF signaling; upon TEV co-culture, CD300a is internalized and co-localizes with EVs in endosomes where it suppresses IFN-β production and the IFN-β-Treg cell axis; CD300a deficiency in DCs led to increased Treg cell numbers in tumors and greater tumor growth. CD300a-deficient mice, B16 melanoma transplant model, co-culture of DCs with TEVs, confocal imaging of CD300a/EV internalization, TLR3-TRIF signaling assays, IFN-β measurements, Treg cell quantification eLife High 34751648
2021 CD300a-deficient neutrophils have impaired phagocytic abilities; despite increased accumulation at the site of UPEC infection, they are unable to reduce bacterial burden; UPEC's α-hemolysin pore-forming toxin induces upregulation of CD300a ligands on infected bladder epithelial cells. CD300a-deficient mice, UPEC urinary tract infection model, phagocytosis assays, bacterial burden quantification, α-hemolysin treatment of bladder epithelial cells with flow cytometric ligand detection European journal of immunology Medium 34268737
2021 CD300a controls neutrophil apoptosis in MSU crystal-induced gout; CD300a agonistic antibody increased apoptosis of human neutrophils via caspase-8 cleavage; CD300a-deficient mice had persistent neutrophil influx, increased IL-1β, and reduced efferocytosis at 24 hours post-MSU injection. CD300a-deficient mice, MSU crystal joint injection model, neutrophil apoptosis assays with CD300a agonistic antibody, caspase-8 cleavage assays, efferocytosis measurements, IL-1β quantification Immunology Medium 34002852
2023 GW0742 (PPARβ/δ agonist) increased expression of PPARβ/δ, CD300a, and phosphorylation of SHP1, and decreased Syk phosphorylation in mast cells after germinal matrix hemorrhage; PPARβ/δ siRNA and CD300a siRNA abolished these effects, placing CD300a downstream of PPARβ/δ and upstream of SHP1/Syk in the pathway regulating mast cell degranulation. GMH rat model, intranasal GW0742 treatment, siRNA knockdown of PPARβ/δ and CD300a, Western blotting for SHP1/Syk phosphorylation, Toluidine Blue staining for mast cell degranulation, behavioral tests Experimental neurology Medium 37995951
2025 CD300a and CD300lf colocalize with PS externalized to the outer leaflet at the cell surface during mast cell activation; CD300lf cooperates with CD300a to inhibit mast cell activation; CD300lf also colocalizes with extracellular ceramide, resulting in stronger inhibition than CD300lf binding to PS alone; double KO mice (CD300a−/−CD300lf−/−) showed lower rectal temperatures in passive systemic anaphylaxis than either single KO. Imaging and flow cytometric analyses of BMMCs from WT, Cd300a−/−, Cd300lf−/−, and Cd300a−/−Cd300lf−/− mice, passive systemic anaphylaxis model, colocalization with PS and ceramide Journal of immunology (Baltimore, Md. : 1950) Medium 40073110
2024 PE serves as a phagocytic ligand for macrophages engaging CD300a; CD300a specifically modulated PE-mediated uptake; CD300a expression curtailed inflammatory responses of macrophages to PE-containing LPS particles; this process involved ITAM-containing adaptors and Syk kinase. Macrophage phagocytosis assays with PE particles, CD300a expression/knockdown, Syk kinase inhibition, ITAM adaptor involvement assays bioRxivpreprint Low
2024 Blocking PS-CD300a signals with antibodies significantly amplified lysis function-related proteins and effector cytokines in NK cells, augmenting their ability to lyse hematologic malignancies; CD300a overexpression inhibited NK-mediated tumor lysis in vitro and shortened survival of HM-xenografted mice. CD300a overexpression, CD300a blocking antibodies, NK cytotoxicity assays, xenotransplantation mouse model, flow cytometry for NK effector proteins Cancer biology & medicine Medium 38425216

Source papers

Stage 0 corpus · 71 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2012 Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 154 22302738
1999 Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. European journal of immunology 137 10540326
2005 The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. Journal of immunology (Baltimore, Md. : 1950) 127 16339535
2005 The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood 108 16254138
2015 The Phosphatidylserine and Phosphatidylethanolamine Receptor CD300a Binds Dengue Virus and Enhances Infection. Journal of virology 86 26468529
2015 The Biology and Disease Relevance of CD300a, an Inhibitory Receptor for Phosphatidylserine and Phosphatidylethanolamine. Journal of immunology (Baltimore, Md. : 1950) 78 25980030
2006 Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. The Journal of allergy and clinical immunology 78 16750992
2012 Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor. The Journal of experimental medicine 75 22826299
2006 Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. The Journal of allergy and clinical immunology 74 17088133
2011 Identification of phosphatidylserine as a ligand for the CD300a immunoreceptor. Biochemical and biophysical research communications 69 22185693
2008 CD300a/c regulate type I interferon and TNF-alpha secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood 65 18535206
2007 The CD300a (IRp60) inhibitory receptor is rapidly up-regulated on human neutrophils in response to inflammatory stimuli and modulates CD32a (FcgammaRIIa) mediated signaling. Molecular immunology 65 17588661
2011 CD300a is expressed on human basophils and seems to inhibit IgE/FcεRI-dependent anaphylactic degranulation. Cytometry. Part B, Clinical cytometry 57 22173928
2008 Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. Journal of immunology (Baltimore, Md. : 1950) 51 18424727
2011 CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection. Blood 50 21482706
2013 The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells. European journal of immunology 49 23640773
2021 CD300a blockade enhances efferocytosis by infiltrating myeloid cells and ameliorates neuronal deficit after ischemic stroke. Science immunology 47 34652960
2012 CD300a and CD300f differentially regulate the MyD88 and TRIF-mediated TLR signalling pathways through activation of SHP-1 and/or SHP-2 in human monocytic cell lines. Immunology 46 22043923
2011 Peripheral CD300a+CD8+ T lymphocytes with a distinct cytotoxic molecular signature increase in pregnant women with chronic chorioamnionitis. American journal of reproductive immunology (New York, N.Y. : 1989) 42 22077960
2000 The CMRF-35H gene structure predicts for an independently expressed member of an ITIM/ITAM pair of molecules localized to human chromosome 17. Tissue antigens 38 10746781
2010 Human Th1 cells that express CD300a are polyfunctional and after stimulation up-regulate the T-box transcription factor eomesodermin. PloS one 35 20498708
2016 Effect of CMV and Aging on the Differential Expression of CD300a, CD161, T-bet, and Eomes on NK Cell Subsets. Frontiers in immunology 34 27872625
2013 Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition. The Journal of biological chemistry 33 23372157
2015 Involvement of CD300a Phosphatidylserine Immunoreceptor in Aluminum Salt Adjuvant-Induced Th2 Responses. Journal of immunology (Baltimore, Md. : 1950) 31 25911756
2021 Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a. eLife 29 34751648
2014 PPARβ/δ activation of CD300a controls intestinal immunity. Scientific reports 28 24958459
2018 Leukocyte CD300a Contributes to the Resolution of Murine Allergic Inflammation. Journal of immunology (Baltimore, Md. : 1950) 26 30315138
2013 The inhibitory receptor CD300a is up-regulated by hypoxia and GM-CSF in human peripheral blood eosinophils. Allergy 24 23346884
2016 CD300c is uniquely expressed on CD56 bright Natural Killer Cells and differs from CD300a upon ligand recognition. Scientific reports 22 27040328
2007 Novel human CD4+ T lymphocyte subpopulations defined by CD300a/c molecule expression. Journal of leukocyte biology 22 17702825
2013 Identification of CD300a as a new hypoxia-inducible gene and a regulator of CCL20 and VEGF production by human monocytes and macrophages. Innate immunity 21 24131792
2012 Expressions and inhibitory functions of CD300a receptors on purified human basophils. Experimental dermatology 21 23163658
2015 Pseudorabies Virus US3 Protein Kinase Protects Infected Cells from NK Cell-Mediated Lysis via Increased Binding of the Inhibitory NK Cell Receptor CD300a. Journal of virology 20 26581992
2021 CD300a and CD300f molecules regulate the function of leukocytes. International immunopharmacology 19 33548578
2017 Differential Effect of Cytomegalovirus Infection with Age on the Expression of CD57, CD300a, and CD161 on T-Cell Subpopulations. Frontiers in immunology 19 28626460
2012 Functional requirements for inhibitory signal transmission by the immunomodulatory receptor CD300a. BMC immunology 19 22537350
2011 Differential expression of CD300a/c on human TH1 and TH17 cells. BMC immunology 19 22046970
2015 Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma. Oncotarget 17 26435477
2022 CD300a Receptor Blocking Enhances Early Clearance of Leishmania donovani From Its Mammalian Host Through Modulation of Effector Functions of Phagocytic and Antigen Experienced T Cells. Frontiers in immunology 15 35116028
2018 CD300A promotes tumor progression by PECAM1, ADCY7 and AKT pathway in acute myeloid leukemia. Oncotarget 15 29938007
2019 The immunoreceptor CD300a controls the intensity of inflammation and dysfunction in a model of Ag-induced arthritis in mice. Journal of leukocyte biology 13 31107994
2006 Molecular analysis and solution structure from small-angle X-ray scattering of the human natural killer inhibitory receptor IRp60 (CD300a). International journal of biological macromolecules 13 16949664
2018 Overexpression of CD300A inhibits progression of NSCLC through downregulating Wnt/β-catenin pathway. OncoTargets and therapy 11 30573974
2025 Universal protection of allogeneic T-cell therapies from natural killer cells via CD300a agonism. Blood advances 10 39368806
2017 IrC2/Bf - A yeast and Borrelia responsive component of the complement system from the hard tick Ixodes ricinus. Developmental and comparative immunology 10 29061482
2018 Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers. Frontiers in immunology 9 30083165
2021 Impact of Cytomegalovirus and Age on T-Cell Subsets Defined by CD161, CD300a, and/or CD57 Expression in Healthy Andalusians. The journals of gerontology. Series A, Biological sciences and medical sciences 8 33993242
2021 CD300a contributes to the resolution of articular inflammation triggered by MSU crystals by controlling neutrophil apoptosis. Immunology 8 34002852
2021 The inhibitory receptor CD300a is essential for neutrophil-mediated clearance of urinary tract infection in mice. European journal of immunology 8 34268737
2020 Polyfunctional HIV-1 specific response by CD8+ T lymphocytes expressing high levels of CD300a. Scientific reports 8 32269232
2023 Leishmania donovani induces CD300a expression to dampen effector properties of CD11c+ dendritic and antigen activated CD8+ T cells. Acta tropica 7 36610528
2021 Optimizing Bioremediation: Elucidating Copper Accumulation Mechanisms of Acinetobacter sp. IrC2 Isolated From an Industrial Waste Treatment Center. Frontiers in microbiology 7 34795645
2013 Transcriptional profiling of human monocytes identifies the inhibitory receptor CD300a as regulator of transendothelial migration. PloS one 7 24058511
2024 Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies. Cancer biology & medicine 5 38425216
2023 CD300a Regulates Mouse Macrophage Functionality in Allergic Inflammation. International archives of allergy and immunology 5 36928079
2015 Chicken CD300a homolog is found on B lymphocytes, various leukocytes populations and binds to phospholipids. Developmental and comparative immunology 5 25681077
2020 CD300a identifies a CD4+ memory T cell subset with a higher susceptibility to HIV-1 infection. AIDS (London, England) 4 32287074
2025 CD300a: An Innate Immune Checkpoint Shaping Tumor Immunity and Therapeutic Opportunity. Cancers 3 40507267
2024 The Role of TIM-1 and CD300a in Zika Virus Infection Investigated with Cell-Based Electrical Impedance. Biosensors 3 39194591
2023 Development of Monoclonal Antibodies Specific to Either CD300AR111 or CD300AQ111 or Both. Monoclonal antibodies in immunodiagnosis and immunotherapy 3 37902989
2025 Inhibitory immunoreceptors CD300a and CD300lf cooperate to regulate mast cell activation. Journal of immunology (Baltimore, Md. : 1950) 2 40073110
2023 Adjuvantation of whole-killed Leishmania vaccine with anti-CD200 and anti-CD300a antibodies potentiates its efficacy and provides protection against wild-type parasites. Molecular immunology 2 37778149
2018 CD300A inhibits tumor cell growth by downregulating AKT phosphorylation in human glioblastoma multiforme. International journal of clinical and experimental pathology 2 31949725
2025 A Humanized Monoclonal Antibody Against CD300A Ameliorates Acute Ischemic Stroke in Humanized Mice. Monoclonal antibodies in immunodiagnosis and immunotherapy 1 39804190
2025 CD300A+ CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon-Alpha Therapy. Alimentary pharmacology & therapeutics 1 40454546
2023 GW0742 reduces mast cells degranulation and attenuates neurological impairments via PPARβ/δ/CD300a/SHP1 pathway after GMH in neonatal rats. Experimental neurology 1 37995951
2026 Efferocytosis-linked genetic signature predicts rheumatoid arthritis risk and highlights CD300A as a novel target. Immunology letters 0 41621689
2026 CD300a Immunoreceptor Blocking Attenuates Neuronal Apoptosis by Regulating Efferocytosis and Promotes Hindlimb Functional Recovery after Acute Spinal Cord Injury in Mice. Journal of neurotrauma 0 41700726
2026 CD300a as a Potential Immune Checkpoint in Breast Cancer: Insights from in vivo and in vitro Models. International archives of allergy and immunology 0 41871214
2025 Evolutionary analysis of CD300A and CD300C paired receptors in primates. Frontiers in immunology 0 40977689
2023 Human IgMhiCD300a+ B Cells Are Circulating Marginal Zone Memory B Cells That Respond to Pneumococcal Polysaccharides and Their Frequency Is Decreased in People Living with HIV. International journal of molecular sciences 0 37762055

Missed literature

Know a paper Affinage missed for CD300A? Flag it for the maintainers and the community.

No submissions yet.